Harrow, Inc. Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Other
Harrow, Inc. (HROW) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Other of $1.03 million as of 2015-12-31, per its 10-K filed 2016-03-23.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther · last filed 2016-03-23
- 2015-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Other $1.03M.
- 2014-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Other $1.03M; Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Other as first filed $30.00K.
- 2013-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Other $40.00K.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Other | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Other as first filed |
|---|---|---|
| 2015-12-31 | $1.03M 10-K · filed 2016-03-23 | |
| 2014-12-31 | $1.03M 10-K · filed 2016-03-23 | $30.00K 10-K · filed 2015-03-12 |
| 2013-12-31 | $40.00K 10-K · filed 2014-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |